Silence Therapeutics
Stage
PIPE | IPOMarket Cap
0.48BAbout Silence Therapeutics
Silence Therapeutics (LON: SLN) focuses on the development of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins.
Silence Therapeutics Headquarter Location
72 Hammersmith Road
London, England, W14 8TH,
United Kingdom
+44 (0)20 3457 6900
Silence Therapeutics Patents
Silence Therapeutics has filed 51 patents.
The 3 most popular patent topics include:
- Molecular biology
- RNA
- MicroRNA
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/13/2018 | 5/3/2022 | RNA, Molecular biology, Gene expression, MicroRNA, Genetics | Grant |
Application Date | 11/13/2018 |
|---|---|
Grant Date | 5/3/2022 |
Title | |
Related Topics | RNA, Molecular biology, Gene expression, MicroRNA, Genetics |
Status | Grant |
Latest Silence Therapeutics News
Jun 2, 2022
June 02, 2022 07:00 AM Eastern Daylight Time LONDON--( BUSINESS WIRE )--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies Healthcare Conference on Thursday, June 9th at 10:00 a.m. EDT / 2:00 p.m. GMT. A live webcast of the presentation can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company’s website following the conference. About Silence Therapeutics Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/ . Contacts
Silence Therapeutics Web Traffic
Silence Therapeutics Rank
Where is Silence Therapeutics's headquarters?
Silence Therapeutics's headquarters is located at 72 Hammersmith Road, London.
What is Silence Therapeutics's latest funding round?
Silence Therapeutics's latest funding round is PIPE.
Who are the investors of Silence Therapeutics?
Investors of Silence Therapeutics include Deep Track Capital and Mallinckrodt.
Who are Silence Therapeutics's competitors?
Competitors of Silence Therapeutics include Ionis Pharmaceuticals.
You May Also Like
Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.
Akcea Therapeutics (NASDAQ: AKCA) is a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.
Regulus Therapeutics (NASDAQ: RGLS), a biopharmaceutical company, focuses on the discovery and development of drugs that target RNAs to treat a range of diseases in the United States. The Company uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. Its clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 to treat nonalcoholic steatohepatitis in patients with type 2 diabetes/pre-diabetes. The company has strategic alliance with GSK to discover and develop microRNA therapeutics for immuno-inflammatory diseases; Sanofi to discover and develop microRNA therapeutics for fibrotic diseases; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and Biogen to evaluate the use of microRNA signatures as a biomarker for human patients with various sclerosis.
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates.
Alnylam Pharmaceuticals (NASDAQ: ALNY) is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company believes that are many new therapeutic frontiers for its RNA technology, including applications in vaccine development, stem cell biology, bio-processing, genomics and biologics.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.